Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026)
Valneva SE (VALN) posted Total Non-Current Liabilities of $235.4 million for Q1 2026, up 1.46% sequentially from $232.0 million in Q4 2025, and up 11.47% YoY from $211.2 million in Q1 2025.
Analysis
Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Valneva SE has reported Total Non-Current Liabilities for 7 years, with the latest figure at $235.4 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 11.47% year-over-year to $235.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.4 million (up 11.47% YoY) and the FY2025 annual result came in at $232.0 million, up 4.99% from the prior year.
- Total Non-Current Liabilities improved to $235.4 million in Q1 2026 per VALN's latest filing, from $232.0 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $298.6 million in Q1 2022 and troughed at $120.7 million in Q2 2023.
- A 5-year average of $192.7 million and a median of $208.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities tumbled 60.14% in 2022, then jumped 76.52% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $126.7 million in 2022, then jumped by 46.91% to $186.1 million in 2023, then gained by 17.26% to $218.2 million in 2024, then advanced by 6.34% to $232.0 million in 2025, then rose by 1.46% to $235.4 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $235.4 million, $232.0 million, and $172.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 236.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 236.92 Mn |
| Mar 31, 2026 | 235.43 Mn |
| Dec 31, 2025 | 232.03 Mn |
| Sep 30, 2025 | 172.17 Mn |
| Jun 30, 2025 | 181.72 Mn |
| Mar 31, 2025 | 211.21 Mn |
| Dec 31, 2024 | 218.21 Mn |
| Sep 30, 2024 | 208.65 Mn |
| Jun 30, 2024 | 213.01 Mn |
| Mar 31, 2024 | 214.57 Mn |
| Dec 31, 2023 | 186.09 Mn |
| Sep 30, 2023 | 157.70 Mn |
| Jun 30, 2023 | 120.68 Mn |
| Mar 31, 2023 | 130.90 Mn |
| Dec 31, 2022 | 126.67 Mn |
| Sep 30, 2022 | 160.20 Mn |
| Jun 30, 2022 | 208.85 Mn |
| Mar 31, 2022 | 298.60 Mn |
| Dec 31, 2021 | 317.78 Mn |
| Dec 31, 2020 | 233.54 Mn |